The Impact of Remimazolam for Postoperative Sedation on the Left Ventricular Systolic Performance in Cardiac Surgery

Phase 4

• Conditions: Coronary Artery Disease
• Interventions: Drug: Remimazolam Injection [Byfavo]

• Registration Number: NCT05041725
• Lead Sponsor: Konkuk University Medical Center

Brief Summary

This study analyzes the impact of intraoperative Remimazolam infusion for postoperative sedation on the left ventricular global longitude strain (LV-GLS) patients undergoing cardiac surgery

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-31
• Status Verified: 2021-09
• Study First Submitted QC: 2021-09-08
• Last Update Submitted: 2021-09-08
• Study First Posted: 2021-09-13
• Last Update Posted: 2021-09-13
• Study Start: 2021-11-01
• Primary Completion: 2022-11-30
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• elective off-pump coronary artery bypass surgery

Exclusion Criteria

• arrhythmia
• LV ejection fraction < 50 %
• preoperative inotropic support

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
remimazolam infusion	Remimazolam Injection [Byfavo]	Intraoperative remimazolam infusion for postoperative sedation

Primary Outcome Measures

Name	Time	Method
change of the left ventricular global longitudinal strain	1 minutes	mean values of the left ventricular global longitudinal strain after 3 minutes, 5 minutes and 10 minutes after the Remimazolam administration